No pressure then.
Yvonne came to see me three months later and had, by then, stopped smoking. She told me about longstanding health problems dominated by Crohn's disease. This had started in her teens and was diagnosed when she was 17. She had proven osteoporosis, pernicious anaemia and severe interstitial cystitis identified as a small bladder age 17 and formally diagnosed when about 40. Six months earlier she had had her gall bladder removed. She remained under the care of both gastrointestinal and urological teams with rheumatology input for bone monitoring.
Her periods had been heavy and painful from menarche and she started 'the pill' at 15. For some years, she had taken ethinyl estradiol 30 mg/desogestrel 150 mg combined oral contraception (COC) and was critical of the recent brand change. She understood her GP's concern that her age and smoking and 'the pill' posed an unreasonable risk and had stopped smoking six months earlier at the time of the cholecystectomy. The practitioner did not know this and had simply refused to prescribe any more. She had run out of pills the previous month.
She was following the following prescribed medication regimen:
. Amitriptyline 25 mg (for bladder and bowel) at night . Mirabegron 50 mg (for bladder) once a day . Loperamide 2 mg as needed (0-8 a day) for loose stool . Lansoprazole 15 mg for acid reflux . Folic acid 5 mg daily . Peppermint oil capsules as needed . Codeine phosphate as needed (taken rarely) if bowel not otherwise controlled . Hydroxocobalamin 1 mg/1 ml -every three months . iAluril Õ (800 mg/50 ml sodium hyaluronate þ 1 g/ 50 ml sodium chondroitin sulfate) weekly -instilled into the bladder Plus:
. Infliximab infusion used in exacerbations (when Crohn's flared)
Plus, bought over the counter:
. Paracetamol, antacid, multivitamins, turmeric, ginger
While vital to understand her background, none of this told me anything about whether she needed contraception, whether bleeding was a problem and how she felt. We therefore ran through a routine menopause symptom enquiry. This revealed: 
Continued
Bleeding pattern When taking COC had done so continuously without a break. With this she had very occasional bleeding which was like a period but not as heavy or painful as it had been in the past. In the last month, she had had a period which was not as bad as she had feared -minimal loss but still some pain. Other She had always tended to get facial acne and this was unchanged
Yvonne was married but did not need contraception as her husband had had a vasectomy. She was unable to work as her health did not allow reliability. She did some regular exercise including dog walking, had a reasonable diet with adequate calcium, had stopped smoking and her alcohol intake was modest.
Management
My task had become comparatively simple. I did not have to do any persuading. She did not need contraception but did want bleeding control. She did have troublesome symptoms in a typical menopausal pattern and if I could help her to feel better in herself and particularly below the waist, there was potential to make a big difference to her life.
So how did we approach this? The bleeding pattern indicated that Yvonne was peri-rather than postmenopausal. A follicle-stimulating hormone level would not have made any difference to subsequent management and was not sought.
Endometriosis as a further diagnosis was eminently plausible but had never been sought or proven. None the less, Yvonne's story suggested that suppression of residual cycles should help both to avoid some pre menstrual syndrome type symptoms and to manage bleeding. I therefore started by considering which would be the best progestogen to use. Desogestrel 150 mg has clearly been well tolerated within the COC combination. My guess was that poor absorption of the combination had allowed occasional breakthrough cycles. Research in younger women has shown a 75 mg dose to be anovulatory in 97% of women. I would hope 150 mg (two tablets) to continue to provide cycle inhibition most of the time even if absorption were sometimes compromised by the Crohn's. This dose should also provide endometrial protection although not licensed for the indication.
The combination of Crohn's disease and pernicious anaemia will affect many aspects of gut absorption and is linked with a higher risk of osteoporosis. Steroid therapy will have added to this risk. In adding estrogen, an adequate blood level to manage both symptoms and bone risks was needed. To avoid the gut issues, a transdermal delivery route was preferred. In addition, this would avoid hepatic first pass metabolism which is desirable with a history of gall bladder disease (due secretion of degraded steroids in bile). Yvonne was told that an adequate estrogen dose had the potential not simply to prevent loss of bone but to reverse some of her previous loss. It could be regarded as a treatment for osteoporosis.
Of the patches and gel discussed, Yvonne chose to use 0.06% estradiol gel at two measures a day (¼1.5 mg estradiol). Cardiovascular risks were not an issue of concern, as she was slim, normotensive, moderately active and no longer smoking. This regimen would not increase cardiac risk and should offer some protection. I explained that unlike the oral estrogen in 'the pill', evidence suggests that would not raise either stroke or venous thromboembolic risk.
While interstitial cystitis was an established diagnosis, estrogen deficient atrophy would add to the misery and there seemed no harm and potential benefit in adding low potency vaginal estrogen. The choice fell to 0.1% estriol cream for low volume but facility to apply the measured dose with a finger to the urethra and introitus where most discomfort was felt.
Review
Three months later, Yvonne had a big smile and the symptoms review now revealed: I thought that this was as much as we could have hoped for. No changes or modification were needed, and Yvonne knew that tweaking was possible if her situation were to change. Yvonne was delighted and described a sense of liberation. She felt that her life had turned around and told me how she had enjoyed a visit from her toddler step-grandson rather than it being an ordeal. She was on her way to tell the urology nurses that all women should consider hormone replacement therapy (HRT).
This turned out to be relatively simple menopause management in a complex patient. The complexity increased the reasons to use HRT rather than presenting risk. It did affect prescribing decisions, but the formulary is not extensive. With an understanding of the pathophysiology and pharmacology, empirical and pragmatic decisions can be made. Increased confidence in assessment and prescribing would allow more women such as Yvonne to be managed in the primary care setting where multi-morbidity and concomitant medication are the stuff of everyday life.
